<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="review-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">medsovet</journal-id><journal-title-group><journal-title xml:lang="ru">Медицинский Совет</journal-title><trans-title-group xml:lang="en"><trans-title>Meditsinskiy sovet = Medical Council</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2079-701X</issn><issn pub-type="epub">2658-5790</issn><publisher><publisher-name>REMEDIUM GROUP Ltd.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.21518/ms2025-108</article-id><article-id custom-type="elpub" pub-id-type="custom">medsovet-9133</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>АКТУАЛЬНЫЕ ПРОБЛЕМЫ ЭНДОКРИНОЛОГИИ И КАРДИОЛОГИИ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>CURRENT ISSUES IN ENDOCRINOLOGY AND CARDIOLOGY</subject></subj-group></article-categories><title-group><article-title>Применение гиполипидемических средств у пациентов с гиперурикемией на фоне сахарного диабета 2-го типа и атеросклероза</article-title><trans-title-group xml:lang="en"><trans-title>The use of hypolipidemic agents in patients with hyperuricemia on the background of type 2 diabetes mellitus and atherosclerosis</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-3659-3576</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Мосина</surname><given-names>А. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Mosina</surname><given-names>A. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Мосина Анна Алексеевна, ассистент кафедры общей и клинической фармакологии</p><p>603005, Россия, Нижний Новгород, пл. Минина и Пожарского, д. 10/1 </p></bio><bio xml:lang="en"><p>Anna A. Mosina, Assistant of the Department of General and Clinical Pharmacology</p><p>10/1, Minin and Pozharsky Square, Nizhny Novgorod, 603950, Russia</p></bio><email xlink:type="simple">anna.mosina.99@bk.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-8430-237X</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Сорокина</surname><given-names>Ю. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Sorokina</surname><given-names>Yu. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Сорокина Юлия Андреевна, к.б.н., доцент кафедры общей и клинической фармакологии</p><p>603005, Россия, Нижний Новгород, пл. Минина и Пожарского, д. 10/1 </p></bio><bio xml:lang="en"><p>Yulia A. Sorokina, Cand. Sci. (Biol.), Associate Professor of the Department of General and Clinical Pharmacology</p><p>10/1, Minin and Pozharsky Square, Nizhny Novgorod, 603950, Russia</p></bio><email xlink:type="simple">zwx@inbox.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-1480-183X</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Ловцова</surname><given-names>Л. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Lovtsova</surname><given-names>L. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Ловцова Любовь Валерьевна, д.м.н., доцент, заведующая кафедрой общей и клинической фармакологии</p><p>603005, Россия, Нижний Новгород, пл. Минина и Пожарского, д. 10/1 </p></bio><bio xml:lang="en"><p>Lubov V. Lovtsova, Dr. Sci. (Med.), Associate Professor, Head of the Department of General and Clinical Pharmacology</p><p>10/1, Minin and Pozharsky Square, Nizhny Novgorod, 603950, Russia</p></bio><email xlink:type="simple">lovcovalubov@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-9829-9463</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Ураков</surname><given-names>А. Л.</given-names></name><name name-style="western" xml:lang="en"><surname>Urakov</surname><given-names>A. L.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Ураков Александр Ливиевич, д.м.н., профессор, заведующий кафедрой общей и клинической фармакологии</p><p>426034, Россия, Удмуртская Республика, Ижевск, ул. Коммунаров, д. 281 </p></bio><bio xml:lang="en"><p>Aleksandr L. Urakov, Dr. Sci. (Med.), Professor, Head of the Department of General and Clinical Pharmacology</p><p>281, Kommunarov St., Izhevsk, Udmurt Republic, 426034, Russia</p></bio><email xlink:type="simple">urakoval@live.ru</email><xref ref-type="aff" rid="aff-2"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Приволжский исследовательский медицинский университет</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Privolzhsky Research Medical University</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>Ижевская государственная медицинская академия</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Izhevsk State Medical Academy</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2025</year></pub-date><pub-date pub-type="epub"><day>24</day><month>05</month><year>2025</year></pub-date><volume>0</volume><issue>6</issue><fpage>265</fpage><lpage>269</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Мосина А.А., Сорокина Ю.А., Ловцова Л.В., Ураков А.Л., 2025</copyright-statement><copyright-year>2025</copyright-year><copyright-holder xml:lang="ru">Мосина А.А., Сорокина Ю.А., Ловцова Л.В., Ураков А.Л.</copyright-holder><copyright-holder xml:lang="en">Mosina A.A., Sorokina Y.A., Lovtsova L.V., Urakov A.L.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.med-sovet.pro/jour/article/view/9133">https://www.med-sovet.pro/jour/article/view/9133</self-uri><abstract><p>Сахарный диабет (СД) – одна из самых распространенных патологий на сегодняшний день. По данным Федерального регистра сахарного диабета, с каждым годом количество пациентов возрастает приблизительно на 5%. Как правило, анамнез отягощается наличием других сопутствующих патологий. И это касается не только сердечно-сосудистых заболеваний, но также нарушений липидного обмена (дислипидемия, ожирение, атеросклероз), метаболизма и выведения мочевой кислоты (гиперурикемия, подагра). Была выявлена четкая взаимосвязь между осложнениями течения диабета и атеросклероза из-за повышения уровня мочевой кислоты в плазме крови. Это повышение может произойти по нескольким причинам: наследственная предрасположенность, употребление продуктов с высоким содержанием пуриновых соединений и дальнейшее нарушение их выведения, соблюдение строгих диет, интенсивные физические нагрузки. Пациенты, как правило, ощущают выраженную нестерпимую боль в суставах, сопровождающуюся отечностью и покраснением кожных покровов в месте поражения. Следует отметить, что не так давно появилась бессимптомная гиперурикемия, при которой уровень мочевой кислоты достигает критических значений без явных клинических симптомов. Гиперурикемия – это еще один отягощающий фактор для пациентов с диабетом 2-го типа (СД 2-го типа). Важно, что для таких пациентов характерна полипрагмазия. И вот здесь особое внимание необходимо уделять возможности взаимодействия лекарственных препаратов и выявлению дополнительных положительных фармакологических эффектов на сопутствующие патологии. Известно, что множественными эффектами обладают препараты из группы статинов. Именно поэтому изучение всего спектра фармакологических эффектов и возможное их применение в практической медицине остается одной из главных задач фармакотерапии.</p></abstract><trans-abstract xml:lang="en"><p>Diabetes mellitus (DM) is one of the most common pathologies today. According to the Federal Register of Diabetes Mellitus, the number of patients increases by about 5% every year. As a rule, the medical history is complicated by the presence of other concomitant pathologies. And this applies not only to cardiovascular diseases, but also to lipid metabolism disorders (dyslipidemia, obesity, atherosclerosis), uric acid metabolism and excretion (hyperuricemia, gout). There was a clear correlation between complications of diabetes and atherosclerosis due to an increase in uric acid levels in blood plasma. This increase can occur for several reasons. Hereditary predisposition, consumption of foods with a high content of purine compounds and further violation of their excretion, adherence to strict diets, intense physical activity. Patients, as a rule, experience severe unbearable joint pain, swelling and redness of the skin at the site of the lesion. It should be noted that asymptomatic hyperuricemia appeared not so long ago, in which uric acid levels reach critical values without obvious clinical symptoms. Hyperuricemia is another aggravating factor for patients with type 2 diabetes. It is important that such patients are characterized by polyprogmasia. And here, special attention should be paid to the interaction of drugs and the identification of additional positive pharmacological effects on concomitant pathologies. It is known that drugs from the group of statins have multiple effects. That is why the study of the full range of pharmacological effects and their possible application in practical medicine remains one of the main tasks of pharmacotherapy.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>персонализированная фармакотерапия</kwd><kwd>статины</kwd><kwd>плейотропные эффекты</kwd><kwd>уратснижающая терапия</kwd><kwd>подагра</kwd></kwd-group><kwd-group xml:lang="en"><kwd>personalized pharmacotherap</kwd><kwd>statins</kwd><kwd>pleiotropic effects</kwd><kwd>urate-lowering therapy</kwd><kwd>gout</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Полякова ЕА, Конради АО, Баранова ЕИ, Галявич АС, Ионин ВА, Остроумова ОД и др. Актуальные подходы к терапии пациентов с артериальной гипертензией в свете современных рекомендаций. Кардиоваскулярная терапия и профилактика. 2024;23(8):4140. https://doi.org/10.15829/1728-8800-2024-4140.</mixed-citation><mixed-citation xml:lang="en">Polyakova EA, Konradi AO, Baranova EI, Galyavich AS, Ionin VA, Ostroumova OD et al. Current approaches to the treatment of hypertensive patients in view of modern guidelines. Cardiovascular Therapy and Prevention (Russian Federation). 2024;23(8):4140. (In Russ.) https://doi.org/10.15829/1728-8800-2024-4140.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Lin GL, Lin HC, Lin HL, Keller JJ, Wang LH. Association between statin use and the risk of gout in patients with hyperlipidemia: A population-based cohort study. Front Pharmacol. 2023;14:1096999. https://doi.org/10.3389/fphar.2023.1096999.</mixed-citation><mixed-citation xml:lang="en">Lin GL, Lin HC, Lin HL, Keller JJ, Wang LH. Association between statin use and the risk of gout in patients with hyperlipidemia: A population-based cohort study. Front Pharmacol. 2023;14:1096999. https://doi.org/10.3389/fphar.2023.1096999.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Шостак НА, Правдюк НГ, Логинова ТК, Лазаренко ГН. Гиперурикемия, подагра и коморбидность. Клиницист. 2022;16(3):58–64. https://doi.org/10.17650/1818-8338-2022-16-3-K648.</mixed-citation><mixed-citation xml:lang="en">Shostak NA, Pravdyuk NG, Loginova TK, Lazarenko GN. Hyperuricemia, gout and comorbidity. The Сlinician. 2022;16(3):58–64. (In Russ.) https://doi.org/10.17650/1818-8338-2022-16-3-K648.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Воронько ИА. Гиперурикемия – это больше чем подагра. Медицинские новости. 2022;(7):39–41. Режим доступа: https://www.mednovosti.by/journal.aspx?article=9682.</mixed-citation><mixed-citation xml:lang="en">Voronko IA. Hyperuricemia is more than gout. Meditsinskie Novosti. 2022;(7):39–41. (In Russ.) Available at: https://www.mednovosti.by/journal.aspx?article=9682.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Амиров НБ, Наумова АЯ, Фатыхов РГ, Амирова РН. Гиперурикемия: клинические последствия, сердечно-сосудистый риск, современный подход к терапии. Вестник современной клинической медицины. 2022;15(1):95–106. https://doi.org/10.20969/VSKM.2022.15(1).95-106.</mixed-citation><mixed-citation xml:lang="en">Amirov NB, Naumova AYa, Fatykhov RG, Amirova RN. Hyperuricemia: clinical consequences, cardiovascular risk, modern approach to therapy. Bulletin of Contemporary Clinical Medicine. 2022;15(1):95–106. (In Russ.) https://doi.org/10.20969/VSKM.2022.15(1).95-106.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Кутишенко НП, Марцевич СЮ, Загребельный АВ, Лукина ЮВ, Воронина ВП, Дмитриева НА и др. Выявление и лечение гиперурикемии в клинической практике (по данным амбулаторного регистра ПРОФИЛЬ). Рациональная фармакотерапия в кардиологии. 2022;18(4):449–454. https://doi.org/10.20996/1819-6446-2022-08-12.</mixed-citation><mixed-citation xml:lang="en">Kutishenko NP, Martsevich SYu, Zagrebelnyy AV, Lukina YuV, Voronina VP, Dmitrieva N.A et al. Detection and Treatment of Hyperuricemia in Clinical Practice (According to the PROFILE Outpatient Registry). Rational Pharmacotherapy in Cardiology. 2022;18(4):449–454. (In Russ.) https://doi.org/10.20996/1819-6446-2022-08-12.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Куницкая НА, Арьев АЛ, Немировский ВС. Роль мочевой кислоты в развитии сердечно-сосудистых заболеваний: от молекулярных механизмов до клинических проявлений. Врач. 2022;33(6):5–12. https://doi.org/10.29296/25877305-2022-06-01.</mixed-citation><mixed-citation xml:lang="en">Kunitskaya NA, Ariev AL, Nemirovskiy VS. The role of uric acid in the development of cardiovascular diseases: from molecular mechanisms to clinical</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Шабалин ВВ, Гринштейн ЮИ, Руф РР, Самсонов НС. Бессимптомная гиперурикемия: очевидное, спорное, гипотетическое. Профилактическая медицина. 2023;26(7):103–109. https://doi.org/10.17116/profmed202326071103.</mixed-citation><mixed-citation xml:lang="en">manifestations. Vrach. 2022;33(6):5–12. (In Russ.) https://doi.org/10.29296/25877305-2022-06-01.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Кобалава ЖД, Троицкая ЕА. Бессимптомная гиперурикемия и риск развития сердечно-сосудистых и почечных заболеваний. Кардиология. 2020;60(10):113–121. https://doi.org/10.18087/cardio.2020.10.n1153.</mixed-citation><mixed-citation xml:lang="en">Shabalin VV, Grinstein YuI, Ruf RR, Samsonov NS. Asymptomatic hyperuricemia: obvious, controversial, hypothetical. Profilakticheskaya Meditsina. 2023;26(7):103–109. (In Russ.) https://doi.org/10.17116/profmed202326071103.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Пациент с гиперурикемией: алгоритм действий врача и регламентирующие документы. Фармакология &amp; Фармакотерапия. 2021;(1):35–37. Режим доступа: https://elibrary.ru/vmhwzd.</mixed-citation><mixed-citation xml:lang="en">Kobalava ZhD, Troitskaya EA. Asymptomatic Hyperuricemia and Risk of Cardiovascular and Renal Diseases. Kardiologiya. 2020;60(10):113–121. (In Russ.) https://doi.org/10.18087/cardio.2020.10.n1153.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Сивордова ЛЕ, Полякова ЮВ, Папичев ЕВ, Ахвердян ЮР, Заводовский БВ. Клиническое значение колхицина в фармакотерапии кардиоваскулярной патологии у пациентов с гиперурикемией при ревматических заболеваниях. Медицинский совет. 2021;(19):188–199. https://doi.org/10.21518/2079-701X-2021-19-188-199.</mixed-citation><mixed-citation xml:lang="en">A patient with hyperuricemia: the algorithm of the doctor’s actions and regulatory documents. Pharmacology &amp; Pharmacotherapy. 2021;(1):35–37. (In Russ.) Available at: https://elibrary.ru/vmhwzd.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Беляева ИБ, Мазуров ВИ, Петрова МС, Башкинов РА, Фонтуренко АЮ. Международные и российские рекомендации по уратснижающей терапии у коморбидных пациентов с гиперурикемией или подагрой. Эффективная фармакотерапия. 2021;17(7):32–38. Режим доступа: https://elibrary.ru/azngga.</mixed-citation><mixed-citation xml:lang="en">Sivordova LE, Polyakova YuV, Papichev EV, Akhverdyan YuR, Zavodovsky BV. Clinical significance of colchicine in pharmacotherapy of cardiovascular pathology in patients with hyperuricemia in rheumatic diseases. Meditsinskiy Sovet. 2021;(19):188–199. (In Russ.) https://doi.org/10.21518/2079-701X-2021-19-188-199.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Чазова ИЕ, Жернакова ЮВ, Кисляк ОА, Подзолков ВИ, Ощепкова ЕВ, Миронова ОЮ, Блинова НВ. Консенсус по ведению пациентов с гиперурикемией и высоким сердечно-сосудистым риском: 2022. Системные гипертензии. 2022;19(1):5–22. https://doi.org/10.38109/2075-082X-2022-1-5-22.</mixed-citation><mixed-citation xml:lang="en">Belyaeva IB, Mazurov VI, Petrova MS, Bashkinov RA, Fonturenko AYu. International and Russian recommendations for urate-lowering therapy in comorbid patients with hyperuricemia or gout. Effective Pharmacotherapy. 2021;17(7):32–38. (In Russ.) Available at: https://elibrary.ru/azngga.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Попов СВ, Стуров НВ. Сравнительные исследования эффективности нефропротекции при антигиперурикемической терапии у пациентов с хронической болезнью почек. Трудный пациент. 2019;17(10):48–51. (In Russ.) Режим доступа: https://elibrary.ru/hwnyqi.</mixed-citation><mixed-citation xml:lang="en">Chazova IE, Zhernakova YuV, Kislyak OA, Podzolkov VI, Oshchepkova EV, Mironova OYu, Blinova NV. Consensus on patients with hyperuricemia and high cardiovascular risk treatment: 2022. Systemic Hypertension. 2022;19(1):5–22. (In Russ.) https://doi.org/10.38109/2075-082X-2022-1-5-22.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Zhang Z, Xu MH, Wei FJ, Shang LN. Clinical study of different doses of atorvastatin combined with febuxostat in patients with gout and carotid atherosclerosis. Pak J Med Sci. 2020;36(6):1334–1338. https://doi.org/10.12669/pjms.36.6.2945.</mixed-citation><mixed-citation xml:lang="en">Popov SV, Sturov NV. Comparative studies of nephroprotection effectiveness during antihyperuricaemic treatment in patients with chronic kidney disease. Trudnyj Pacient. 2019;17(10):48–51. (In Russ.) Available at: https://elibrary.ru/hwnyqi.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Алекберова ЗС, Насонов ЕЛ. Перспективы применения колхицина в медицине: новые данные. Научно-практическая ревматология. 2020;58(2): 183–190. Режим доступа: https://rsp.mediar-press.net/rsp/article/view/2876.</mixed-citation><mixed-citation xml:lang="en">Zhang Z, Xu MH, Wei FJ, Shang LN. Clinical study of different doses of atorvastatin combined with febuxostat in patients with gout and carotid atherosclerosis. Pak J Med Sci. 2020;36(6):1334–1338. https://doi.org/10.12669/pjms.36.6.2945.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Sumpter NA, Saag KG, Reynolds RJ, Merriman TR. Comorbidities in gout and hyperuricemia: causality or epiphenomena? Curr Opin Rheumatol. 2020;32(2):126–133. https://doi.org/10.1097/BOR.0000000000000691.</mixed-citation><mixed-citation xml:lang="en">Alekberova ZS, Nasonov EL. Prospects for using colchicine in medicine: new evidence. Rheumatology Science and Practice. 2020;58(2):183–190. (In Russ.) Available at: https://rsp.mediar-press.net/rsp/article/view/2876.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Kimura Y, Tsukui D, Kono H. Uric Acid in Inflammation and the Pathogenesis of Atherosclerosis. Int J Mol Sci. 2021;22(22):12394. https://doi.org/10.3390/ijms222212394.</mixed-citation><mixed-citation xml:lang="en">Sumpter NA, Saag KG, Reynolds RJ, Merriman TR. Comorbidities in gout and hyperuricemia: causality or epiphenomena? Curr Opin Rheumatol. 2020;32(2):126–133. https://doi.org/10.1097/BOR.0000000000000691.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Lee TS, Lu TM, Chen CH, Guo BC, Hsu CP. Hyperuricemia induces endothelial dysfunction and accelerates atherosclerosis by disturbing the asymmetric dimethylarginine/dimethylarginine dimethylaminotransferase 2 pathway. Redox Biol. 2021;46:102108. https://doi.org/10.1016/j.redox.2021.102108.</mixed-citation><mixed-citation xml:lang="en">Kimura Y, Tsukui D, Kono H. Uric Acid in Inflammation and the Pathogenesis of Atherosclerosis. Int J Mol Sci. 2021;22(22):12394. https://doi.org/10.3390/ijms222212394.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">He B, Nie Q, Wang F, Wang X, Zhou Y, Wang C et al. Hyperuricemia promotes the progression of atherosclerosis by activating endothelial cell pyroptosis via the ROS/NLRP3 pathway. J Cell Physiol. 2023;238(8):1808–1822. https://doi.org/10.1002/jcp.31038.</mixed-citation><mixed-citation xml:lang="en">Lee TS, Lu TM, Chen CH, Guo BC, Hsu CP. Hyperuricemia induces endothelial dysfunction and accelerates atherosclerosis by disturbing the asymmetric dimethylarginine/dimethylarginine dimethylaminotransferase 2 pathway. Redox Biol. 2021;46:102108. https://doi.org/10.1016/j.redox.2021.102108.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Nishizawa H, Maeda N, Shimomura I. Impact of hyperuricemia on chronic kidney disease and atherosclerotic cardiovascular disease. Hypertens Res. 2022;45(4):635–640. https://doi.org/10.1038/s41440-021-00840-w.</mixed-citation><mixed-citation xml:lang="en">He B, Nie Q, Wang F, Wang X, Zhou Y, Wang C et al. Hyperuricemia promotes the progression of atherosclerosis by activating endothelial cell pyroptosis via the ROS/NLRP3 pathway. J Cell Physiol. 2023;238(8):1808–1822. https://doi.org/10.1002/jcp.31038.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Rafiullah M, Siddiqui K, Al-Rubeaan K. Association between serum uric acid levels and metabolic markers in patients with type 2 diabetes from a community with high diabetes prevalence. Int J Clin Pract. 2020;74(4):e13466. https://doi.org/10.1111/ijcp.13466.</mixed-citation><mixed-citation xml:lang="en">Nishizawa H, Maeda N, Shimomura I. Impact of hyperuricemia on chronic kidney disease and atherosclerotic cardiovascular disease. Hypertens Res. 2022;45(4):635–640. https://doi.org/10.1038/s41440-021-00840-w.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Siniscalchi C, Basaglia M, Riva M, Meschi M, Meschi T, Castaldo G, Di Micco P. Statins Effects on Blood Clotting: A Review. Cells. 2023;12(23):2719. https://doi.org/10.3390/cells12232719.</mixed-citation><mixed-citation xml:lang="en">Rafiullah M, Siddiqui K, Al-Rubeaan K. Association between serum uric acid levels and metabolic markers in patients with type 2 diabetes from a community with high diabetes prevalence. Int J Clin Pract. 2020;74(4):e13466. https://doi.org/10.1111/ijcp.13466.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Мадянов ИВ. Взаимоотношения при сахарном диабете 2 типа основных параметров мочекислого обмена с показателями инсулинорезистентности. Бюллетень науки и практики. 2020;6(1):122–128. https://doi.org/10.33619/2414-2948/50/13.</mixed-citation><mixed-citation xml:lang="en">Siniscalchi C, Basaglia M, Riva M, Meschi M, Meschi T, Castaldo G, Di Micco P. Statins Effects on Blood Clotting: A Review. Cells. 2023;12(23):2719. https://doi.org/10.3390/cells12232719.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Мадянов ИВ. Гиперурикемия и сахарный диабет. РМЖ. Медицинское обозрение. 2019;3(1):20–24. Режим доступа: https://www.rmj.ru/articles/endokrinologiya/Giperurikemiya_i_saharnyy_diabet/.</mixed-citation><mixed-citation xml:lang="en">Madyanov IV. Relationships with type 2 diabetes mellitus of the basic parameters of urine acid metabolism with indicators of insulin resistance. Bulletin of Science and Practice. 2020;6(1):122–128. https://doi.org/10.33619/2414-2948/50/13.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Сорокина ЮА, Ловцова ЛВ, Ураков АЛ, Занозина ОВ. Генетический полиморфизм у пациентов с впервые выявленным сахарным диабетом 2-го типа. Современные технологии в медицине. 2019;11(2):57–62. https://doi.org/10.17691/stm2019.11.2.08.</mixed-citation><mixed-citation xml:lang="en">Madyanov IV. Hyperuricemia and diabetes mellitus. RMJ. Medical Review. 2019;3(1):20–24. (In Russ.) Available at: https://www.rmj.ru/articles/endokrinologiya/Giperurikemiya_i_saharnyy_diabet/.</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Занозина ОВ, Сорокина ЮА, Ловцова ЛВ, Ураков АЛ. Глиптины в инкретин-направленной фармакотерапии сахарного диабета: возможности и персонализация. Нижний Новгород: Ремедиум Приволжье; 2018. 112 с. Режим доступа: https://medialnn.ru/?id=17467&amp;download=1.</mixed-citation><mixed-citation xml:lang="en">Sorokina YuA, Lovtsova LV, Urakov AL, Zanozina OV. Genetic Polymorphism in Patients with Newly Diagnosed Type 2 Diabetes Mellitus. Sovremennye Tehnologii v Medicine. 2019;11(2):57–62. (In Russ.) https://doi.org/10.17691/stm2019.11.2.08.</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Urakov AL, Sorokina YA, Lovtsova LV. 2022. “Long COVID” Molecular Genetic Markers in Patients with Type 2 Diabetes Mellitus. Med Res Arch. 2022;10(7). https://doi.org/10.18103/mra.v10i7.2933.</mixed-citation><mixed-citation xml:lang="en">Занозина ОВ, Сорокина ЮА, Ловцова ЛВ, Ураков АЛ. Глиптины в инкретин-направленной фармакотерапии сахарного диабета: возможности и персонализация. Нижний Новгород: Ремедиум Приволжье; 2018. 112 с. Режим доступа: https://medialnn.ru/?id=17467&amp;download=1.</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Руда ММ, Карпов ЮА. Гиперурикемия и сердечно-сосудистый риск: современный взгляд на проблему. Атмосфера. Новости кардиологии. 2020;(1):3–14. Режим доступа: https://www.elibrary.ru/bmqqan.</mixed-citation><mixed-citation xml:lang="en">Urakov AL, Sorokina YA, Lovtsova LV. 2022. “Long COVID” Molecular Genetic Markers in Patients with Type 2 Diabetes Mellitus. Med Res Arch. 2022;10(7). https://doi.org/10.18103/mra.v10i7.2933.</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">McCormick N, O’Connor MJ, Yokose C, Merriman TR, Mount DB, Leong A, Choi HK. Assessing the Causal Relationships Between Insulin Resistance and Hyperuricemia and Gout Using Bidirectional Mendelian Randomization. Arthritis Rheumatol.2021;73(11):2096–2104. https://doi.org/10.1002/art.41779.</mixed-citation><mixed-citation xml:lang="en">Ruda MМ, Karpov YuA. Hyperuricemia and cardiovascular risk: modern view on the problem. Atmosphere. Cardiology News. 2020;(1):3–14. (In Russ.) Available at: https://www.elibrary.ru/bmqqan.</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Изможерова НВ, Попов АА, Курындина АА, Гаврилова ЕИ, Шамбатов МА, Бахтин ВМ. Полиморбидность и полипрагмазия у пациентов высокого и очень высокого сердечно-сосудистого риска. Рациональная фармакотерапия в кардиологии. 2022;18(1):20–26. https://doi.org/10.20996/1819-6446-2022-02-09.</mixed-citation><mixed-citation xml:lang="en">McCormick N, O’Connor MJ, Yokose C, Merriman TR, Mount DB, Leong A, Choi HK. Assessing the Causal Relationships Between Insulin Resistance and Hyperuricemia and Gout Using Bidirectional Mendelian Randomization. Arthritis Rheumatol.2021;73(11):2096–2104. https://doi.org/10.1002/art.41779.</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Лебедев ПА, Волова ЛТ, Осина НК, Паранина ЕВ. Инфламмасома NLRP3 – новая универсальная мишень терапевтического воздействия у пациентов с бессимптомной гиперурикемией и подагрой. Рациональная фармакотерапия в кардиологии. 2024;20(3):331–339. https://doi.org/10.20996/1819-6446-2024-3018.</mixed-citation><mixed-citation xml:lang="en">Izmozherova NV, Popov AA, Kuryndina AA, Gavrilova EI, Shambatov MA, Bakhtin VM. Polymorbidity and Polypragmasia in High and Very High Cardiovascular Risk Patients. Rational Pharmacotherapy in Cardiology. 2022;18(1):20–26. (In Russ.) https://doi.org/10.20996/1819-6446-2022-02-09.</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Urakov AL, Sorokina YuA, Lovtsova LV, Makarova EV, Zanozina OV. Novel Predictors for Personalized Pharmacotherapy in Type 2 Diabetes and COPD. Adv Biores. 2021;12(2):241–245. Available at: https://soeagra.com/abr/abrmarch2021/35.pdf.</mixed-citation><mixed-citation xml:lang="en">Lebedev PA, Volova LT, Osina NK, Paranina EV. NLRP3 Inflammasome – a new universal target of asymptomatic hyperuricemia and gout management. Rational Pharmacotherapy in Cardiology. 2024;20(3):331–339. (In Russ.) https://doi.org/10.20996/1819-6446-2024-3018.</mixed-citation></citation-alternatives></ref><ref id="cit34"><label>34</label><citation-alternatives><mixed-citation xml:lang="ru">Мусаева НЗ, Ощепкова ЕВ, Аксенова АВ, Гурциев ТМ, Чазова ИЕ. Связь мочевой кислоты с факторами риска сердечно-сосудистых заболеваний у больных артериальной гипертонией. Системные гипертензии. 2023;20(3):19–25. https://doi.org/10.38109/2075-082X-2023-3-19-25.</mixed-citation><mixed-citation xml:lang="en">Urakov AL, Sorokina YuA, Lovtsova LV, Makarova EV, Zanozina OV. Novel Predictors for Personalized Pharmacotherapy in Type 2 Diabetes and COPD. Adv Biores. 2021;12(2):241–245. Available at: https://soeagra.com/abr/abrmarch2021/35.pdf.</mixed-citation></citation-alternatives></ref><ref id="cit35"><label>35</label><citation-alternatives><mixed-citation xml:lang="ru">Prado Y, Aravena D, Llancalahuen FM, Aravena C, Eltit F, Echeverría C et al. Statins and Hemostasis: Therapeutic Potential Based on Clinical Evidence. Adv Exp Med Biol. 2023;1408:25–47. https://doi.org/10.1007/978-3-031-26163-3_2.</mixed-citation><mixed-citation xml:lang="en">Musaeva NZ, Oshchepkova EV, Aksenova AV, Gurtsiev TM, Chazova IE. Connection between uric acid and cardiovascular risk factors in hypertensive patients. Systemic Hypertension. 2023;20(3):19–25. (In Russ.) https://doi.org/10.38109/2075-082X-2023-3-19-25.</mixed-citation></citation-alternatives></ref><ref id="cit36"><label>36</label><citation-alternatives><mixed-citation xml:lang="ru">Великая ОВ, Недомолкина СА, Недомолкин СВ. Оценка влияния статинов на цитокиновый и эндотелиальный дисбалансу больных хронической обструктивной болезнью легких и сахарным диабетом. Лечащий врач. 2020;(3):22–25. https://doi.org/10.26295/OS.2020.67.66.003.</mixed-citation><mixed-citation xml:lang="en">Prado Y, Aravena D, Llancalahuen FM, Aravena C, Eltit F, Echeverría C et al. Statins and Hemostasis: Therapeutic Potential Based on Clinical Evidence. Adv Exp Med Biol. 2023;1408:25–47. https://doi.org/10.1007/978-3-031-26163-3_2.</mixed-citation></citation-alternatives></ref><ref id="cit37"><label>37</label><citation-alternatives><mixed-citation xml:lang="ru">Abrahami D, Hudson M, Suissa S. Statins and lower mortality in rheumatic diseases: An effect of immortal time bias? Semin Arthritis Rheum. 2021;51(1):211–218. https://doi.org/10.1016/j.semarthrit.2020.11.010.</mixed-citation><mixed-citation xml:lang="en">Velikaya OV, Nedomolkina SA, Nedomolkin SV. Evaluation of the effect of statins on cytokine and endothelial imbalances in patients with chronic obstructive pulmonary disease and diabetes mellitus. Lechaschi Vrach. 2020;(3):22–25. (In Russ.) https://doi.org/10.26295/OS.2020.67.66.003.</mixed-citation></citation-alternatives></ref><ref id="cit38"><label>38</label><citation-alternatives><mixed-citation xml:lang="ru">Okyay K. Pleiotropic effects of statins: New evidences. Turk Kardiyol Dern Ars. 2021;49(7):533–535. https://doi.org/10.5543/tkda.2021.21211.</mixed-citation><mixed-citation xml:lang="en">Abrahami D, Hudson M, Suissa S. Statins and lower mortality in rheumatic diseases: An effect of immortal time bias? Semin Arthritis Rheum. 2021;51(1):211–218. https://doi.org/10.1016/j.semarthrit.2020.11.010.</mixed-citation></citation-alternatives></ref><ref id="cit39"><label>39</label><citation-alternatives><mixed-citation xml:lang="ru">Akbari A, Razmi M, Rafiee M, Watts GF, Sahebkar A. The Effect of Statin Therapy on Serum Uric Acid Levels: A Systematic Review and Metaanalysis. Curr Med Chem. 2024;31(13):1726–1739. https://doi.org/10.2174/0929867330666230207124516.</mixed-citation><mixed-citation xml:lang="en">Okyay K. Pleiotropic effects of statins: New evidences. Turk Kardiyol Dern Ars. 2021;49(7):533–535. https://doi.org/10.5543/tkda.2021.21211.</mixed-citation></citation-alternatives></ref><ref id="cit40"><label>40</label><citation-alternatives><mixed-citation xml:lang="ru">Kim M, Kim SE, Lee SM, An WS. Effect of pitavastatin on erythrocyte membrane fatty acid content in patients with chronic kidney disease: two-arm parallel randomized controlled trial. J Yeungnam Med Sci. 2024;41(3):188–195. https://doi.org/10.12701/jyms.2024.00094.</mixed-citation><mixed-citation xml:lang="en">Akbari A, Razmi M, Rafiee M, Watts GF, Sahebkar A. The Effect of Statin Therapy on Serum Uric Acid Levels: A Systematic Review and Metaanalysis. Curr Med Chem. 2024;31(13):1726–1739. https://doi.org/10.2174/0929867330666230207124516.</mixed-citation></citation-alternatives></ref><ref id="cit41"><label>41</label><citation-alternatives><mixed-citation xml:lang="ru">Kim M, Kim SE, Lee SM, An WS. Effect of pitavastatin on erythrocyte membrane fatty acid content in patients with chronic kidney disease: two-arm parallel randomized controlled trial. J Yeungnam Med Sci. 2024;41(3):188–195. https://doi.org/10.12701/jyms.2024.00094.</mixed-citation><mixed-citation xml:lang="en">Kim M, Kim SE, Lee SM, An WS. Effect of pitavastatin on erythrocyte membrane fatty acid content in patients with chronic kidney disease: two-arm parallel randomized controlled trial. J Yeungnam Med Sci. 2024;41(3):188–195. https://doi.org/10.12701/jyms.2024.00094.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
